Showing results (2331-2340 of 3,057) with videos related to
Sort By:
Pageof 306
Scientific Data|January 11, 2025
BOston Neonatal Brain Injury Data for Hypoxic Ischemic Encephalopathy (BONBID-HIE): I. MRI and Lesion LabelingRina Bao, Ya'nan Song, Sara V Bates, et al.Perfusion|February 23, 2007
Comparison of hollow-fiber membrane oxygenators with different perfusion modes during normothermic and hypothermic CPB in a simulated neonatal modelAkif Undar, Bingyang Ji, Branka Lukic, et al.Journal of Bacteriology|April 8, 2015
Resources for Genetic and Genomic Analysis of Emerging Pathogen Acinetobacter baumanniiLarry A Gallagher, Elizabeth Ramage, Eli J Weiss, et al.ESMO Open|August 30, 2017
Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortHoward A Burris, Suzanne Bakewell, Johanna C Bendell, et al.Scientific Reports|August 18, 2022
Spatiotemporal mapping of malaria incidence in Sudan using routine surveillance dataAhmed Elagali, Ayman Ahmed, Nada Makki, et al.Frontiers in Immunology|September 13, 2021
Immunopotentiation by Lymph-Node Targeting of a Malaria Transmission-Blocking NanovaccineGregory P Howard, Nicole G Bender, Prachi Khare, et al.Journal of Cardiothoracic and Vascular Anesthesia|January 27, 2015
The functional aortic annulus in the 3D era: focus on transcatheter aortic valve replacement for the perioperative echocardiographerPrakash A Patel, Jacob T Gutsche, William J Vernick, et al.International Journal of Environmental Research and Public Health|September 25, 2019
Mapping Geospatial Processes Affecting the Environmental Fate of Agricultural Pesticides in AfricaChantal M J Hendriks, Harry S Gibson, Anna Trett, et al.Cancer Chemotherapy and Pharmacology|March 11, 2014
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumorsKelly K Curtis, John Sarantopoulos, Donald W Northfelt, et al.British Journal of Pharmacology|May 4, 2018
LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environmentRong Fu, Yi-Wei Zhang, Hong-Mei Li, et al.Pageof 306